Employees: 822
Size Seegene (096530.KS) is a South Korea Health Care company (Medical Specialties) with a market value of $808M, the 272nd largest of 483 South Korea companies the cockpit tracks. Shares closed at ₩23,700 on 18 Nov 2026.
Performance Over six months the shares fell 25.9%, against -12.6% for the median peer and -37.2% for the South Korea market (cap-weighted) — 7th lowest of 21 in its peer set.
Growth Revenue grew 13.1% over the last twelve months (peer median +7.3%); the operating margin is 13.1% (peer median 10.2%).
Valuation It trades at 20.0× forward earnings against a peer median of 19.9× (7th most expensive of 14).
Price implies For today's price to make sense, revenue must grow about -7% a year for seven years (Req g). Recent delivered growth is -16%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 2.3 points above its cost of capital (6.5% WACC).
Next results Next results expected around 18 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | ₩519B | ₩474B | ₩414B | ₩367B | ₩854B |
| Revenue growth | — | +14% | +13% | -57% | — |
| Gross profit | ₩313B | ₩271B | ₩205B | ₩180B | ₩466B |
| EBITDA | ₩133B | ₩105B | ₩54.7B | ₩35.7B | ₩239B |
| Net income | ₩46.8B | ₩48.3B | -₩8.76B | ₩669M | ₩182B |
| Free cash flow | ₩95.5B | ₩112B | ₩45.4B | ₩69.8B | ₩256B |
| Capital expenditure | ₩72.0B | ₩40.5B | ₩43.6B | ₩31.9B | ₩72.5B |
| Total debt | ₩124B | ₩130B | ₩144B | ₩142B | ₩159B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 096530.KS | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -35.8% | -4.8% | lowest of 21 |
| 6-month return | -25.9% | -12.6% | 7th lowest of 21 |
| Distance from 52-week high | -41.4% | -37.6% | 9th lowest of 21 |
| Revenue growth (TTM) | +13.1% | +7.3% | 9th highest of 21 |
| Operating margin | 13.1% | 10.2% | 8th highest of 21 |
| Forward P/E | 20.0× | 19.9× | 7th most expensive of 14 |
| Growth the price implies (Req g, 7 yrs) | -6.7% | 10.4% | 3rd least demanding of 15 |
| Growth delivered (Del g) | -15.9% | +11.8% | lowest of 15 |
| Hurdle (Req g minus delivered) | +9.2 pp | +2.6 pp | 6th most demanding of 15 |
| ROIC minus cost of capital | +2.3 pp | -1.3 pp | 7th highest of 21 |
| EV / EBITDA | 4.9× | 14.7× | cheapest of 9 |
| Net debt / EBITDA | -3.2× | 0.3× | 3rd least indebted of 10 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Seegene 096530.KS | South Korea | $808M | -26% | +13% | 13% | 20.0× | -6.7% | -15.9% |
| Advanced Medical Solutions AMS.L | United Kingdom | $811M | +27% | +6% | 12% | 20.7× | 20.0% | +21.4% |
| MedCap MCAP.ST | Sweden | $811M | -4% | +17% | 15% | 25.8× | 2.7% | +20.9% |
| Beijing Hotgen Biotech 688068.SS | China | $815M | -37% | +8% | -94% | n/a | n/a | n/a |
| Ningbo Jansen Superconducting Technologies 688805.SS | China | $818M | -36% | +36% | 16% | n/a | 35.6% | +17.1% |
| OrthoPediatrics KIDS | United States | $826M | +71% | +16% | -8% | n/a | n/a | n/a |
| Standard Engineering Technology SETL.NS | India | $783M | +168% | +45% | 14% | n/a | n/a | n/a |
| Cofoe Medical Technology 1187.HK | Hong Kong | $836M | -11% | +40% | 10% | 13.1× | -6.4% | +6.6% |
| Beta Bionics BBNX | United States | $779M | +42% | +44% | -73% | n/a | n/a | n/a |
| Mesa Laboratories MLAB | United States | $775M | +33% | +2% | 10% | 11.5× | 21.3% | +13.2% |
| Cytek Biosciences CTKB | United States | $774M | +57% | +6% | -21% | n/a | n/a | n/a |
| Cisen Pharmaceutical 603367.SS | China | $843M | -15% | -6% | 8% | 7.9× | -14.6% | -1.3% |
| Modern Dental 3600.HK | Hong Kong | $844M | +24% | +12% | 22% | 8.5× | -7.1% | +11.3% |
| LifeTech Scientific 1302.HK | Hong Kong | $771M | -30% | +1% | 12% | 19.8× | 9.6% | +15.5% |
| Varex Imaging VREX | United States | $771M | +79% | +5% | 8% | 19.9× | n/a | n/a |
| Zylox-Tonbridge Medical Technology 2190.HK | Hong Kong | $768M | -16% | +39% | 25% | 14.4× | 3.8% | +105.8% |
| Shantou Institute of Ultrasonic Instruments 301602.SZ | China | $858M | -25% | +4% | 30% | n/a | 11.1% | +4.6% |
| HOB Biotech 688656.SS | China | $858M | -33% | +6% | 7% | 166.9× | 37.6% | +12.4% |
| Maccura Biotechnology 300463.SZ | China | $756M | -18% | -1% | -4% | 421.0× | 7.9% | -10.2% |
| Beijing SDL Technology 002658.SZ | China | $864M | -34% | -13% | 9% | 22.4× | 16.8% | +2.9% |
| Sino Medical Sciences Technology 688108.SS | China | $753M | -41% | +22% | 19% | 60.0× | 27.9% | +9.9% |